14 Facts About Keith Yamamoto

Keith R Yamamoto was born on February 4,1946 and is vice chancellor of science policy and strategy and professor of cellular and molecular pharmacology at the University of California, San Francisco,.

Keith Yamamoto holds the position of director of UCSF Precision Medicine.

Keith Yamamoto is known for his molecular biology and biochemistry research on nuclear receptors and his involvement in science policy and precision medicine.

Keith Yamamoto earned his doctorate in biochemical sciences at Princeton University in 1973 in the laboratory of Bruce Alberts for his research on the estrogen receptor.

Keith Yamamoto then began his research on the glucocorticoid receptor as a postdoctoral fellow with Gordon Tomkins at UCSF.

In 1976, Keith Yamamoto joined the Department of Biochemistry and Biophysics at the University of California, San Francisco as an assistant professor.

Keith Yamamoto took on the role of vice-chair of the Department of Biochemistry and Biophysics at UCSF in 1985.

In 2015, Keith Yamamoto became UCSF's first vice chancellor of science policy and strategy.

Keith Yamamoto was previously the vice chancellor of research for the university, and the vice dean, research, within the School of Medicine.

Keith Yamamoto was elected a fellow of the American Academy of Arts and Sciences in 1989, elected to the National Academy of Sciences in 1989, and to the American Association for the Advancement of Science in 2002.

Keith Yamamoto ran a research lab focused on understanding signaling and transcriptional control by nuclear receptors and continues to teach graduate courses in molecular biology and biochemistry at UCSF.

Keith Yamamoto has served on several committees that oversee the NIH peer-review process which allocates funding to research investigators.

Keith Yamamoto was chairman of the NIH Center for Scientific Review Advisory Committee from 1996 to 2000.

Keith Yamamoto had advocated for streamlining the science grant review process and for devising strategies for focusing NIH funding on research that will have the greatest impact in the field.